The U.S. Food and Drug Administration on Monday approved the use of the antiviral therapy, remdesivir, to treat COVID-19 in infants 4 weeks and older, despite having no evidence the treatment is effective or even safe for young children.
top of page
To see this working, head to your live site.
1764. FDA Rubber-Stamps Remdesivir for Infants Without Evidence of Safety, Efficacy
1764. FDA Rubber-Stamps Remdesivir for Infants Without Evidence of Safety, Efficacy
0 comments
Like
Comments (0)
Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page